Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07537075) titled 'An Open Label Extension of SKY-0515 in Participants With Huntington's Disease' on April 3.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Skyhawk Therapeutics, Inc.

Condition: Huntington's Disease (HD)

Intervention: Drug: SKY-0515

Recruitment Status: Not recruiting

Phase: Phase 2/Phase 3

Date of First Enrollment: April 10, 2026

Target Sample Size: 500

Countries of Recruitment: Australia

To know more, visit https://clinicaltrials.gov/study/NCT07537075

Published by HT Digita...